HomeCompareSSMFF vs PFE

SSMFF vs PFE: Dividend Comparison 2026

SSMFF yields 13.13% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $2.1K in total portfolio value· pulled ahead in Year 10
10 years
SSMFF
SSMFF
● Live price
13.13%
Share price
$15.23
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.5K
Annual income
$2,970.58
Full SSMFF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SSMFF vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSMFFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSMFF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSMFF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSMFF
Annual income on $10K today (after 15% tax)
$1,116.22/yr
After 10yr DRIP, annual income (after tax)
$2,524.99/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $19,794.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSMFF + PFE for your $10,000?

SSMFF: 50%PFE: 50%
100% PFE50/50100% SSMFF
Portfolio after 10yr
$48.5K
Annual income
$14,614.65/yr
Blended yield
30.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SSMFF
No analyst data
Altman Z
3.4
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSMFF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSMFFPFE
Forward yield13.13%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$47.5K$49.6K
Annual income after 10y$2,970.58$26,258.71
Total dividends collected$21.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SSMFF vs PFE ($10,000, DRIP)

YearSSMFF PortfolioSSMFF Income/yrPFE PortfolioPFE Income/yrGap
1$12,013$1,313.20$9,153$693.39+$2.9KSSMFF
2$14,328$1,474.36$8,593$849.25+$5.7KSSMFF
3$16,975$1,643.47$8,336$1,066.78+$8.6KSSMFF
4$19,983$1,819.65$8,437$1,384.80+$11.5KSSMFF
5$23,384$2,001.95$9,013$1,875.40+$14.4KSSMFF
6$27,210$2,189.39$10,306$2,680.72+$16.9KSSMFF
7$31,495$2,380.97$12,820$4,101.38+$18.7KSSMFF
8$36,276$2,575.68$17,673$6,826.70+$18.6KSSMFF
9$41,588$2,772.54$27,543$12,591.86+$14.0KSSMFF
10← crossover$47,469$2,970.58$49,560$26,258.71$2.1KPFE

SSMFF vs PFE: Complete Analysis 2026

SSMFFStock

SFC Energy AG develops, produces, and distributes systems and solutions for stationary and mobile off-grid power supply based on hydrogen and direct methanol fuel cells worldwide. The company operates in two segments, Clean Energy and Clean Power Management. It offers EFOY Hydrogen 2.5 fuel cells for higher power ranges; EFOY Pro fuel cells for on-board power supply in vehicles, as well as off-grid power supply, such as monitoring systems, measuring stations, and oil and gas applications; EFOY fuel cells, which ensures automatic recharge of the batteries; SFC EMILY for military and security applications; SFC JENNY, a portable fuel cell for military applications; and SFC Power Manager 3G, a portable power distributor and battery charger that enables the soldiers to use various energy sources available in the field, such as hybrid batteries, solar panels, and vehicle power and fuel cells to power devices or charge batteries. The company also provides EFOY ProCube, a mobile and maintenance-free solution for off-grid power supplies; EFOY ProEnergyBox, an off-grid energy solution for weather conditions; EFOY ProEnergyCase, a portable and maintenance-free solution for grid-independent power supplies; EFOY ProCabinet, an insulated outdoor energy solution for remote off-grid power supply; EFOY ProTrailer, a trailer-based energy solution; drives and motor solutions; SCADA and telemetry solutions; and coils and linear drives. In addition, it offers accessories and spare parts, such as fuel cartridges; and mechanical, electronic, and electrical instruments to monitor and control production and logistics processes. The company was formerly known as SFC Smart Fuel Cell AG and changed its name to SFC Energy AG in July 2010. SFC Energy AG was founded in 2000 and is headquartered in Brunnthal, Germany.

Full SSMFF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SSMFF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSMFF vs SCHDSSMFF vs JEPISSMFF vs OSSMFF vs KOSSMFF vs MAINSSMFF vs JNJSSMFF vs MRKSSMFF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.